Io Biotech Stock Beta
| IOBT Stock | USD 0.89 0.04 4.71% |
IO Biotech fundamentals help investors to digest information that contributes to IO Biotech's financial success or failures. It also enables traders to predict the movement of IOBT Stock. The fundamental analysis module provides a way to measure IO Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IO Biotech stock.
IOBT | Beta |
IO Biotech Company Beta Analysis
IO Biotech's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current IO Biotech Beta | 0.42 |
Most of IO Biotech's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IO Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
IOBT Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for IO Biotech is extremely important. It helps to project a fair market value of IOBT Stock properly, considering its historical fundamentals such as Beta. Since IO Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of IO Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of IO Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, IO Biotech has a Beta of 0.419. This is 51.28% lower than that of the Biotechnology sector and 69.86% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
IOBT Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IO Biotech's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IO Biotech could also be used in its relative valuation, which is a method of valuing IO Biotech by comparing valuation metrics of similar companies.IO Biotech is currently under evaluation in beta category among its peers.
IO Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in IO Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of IO Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing IO Biotech's value.| Shares | Ubs Group Ag | 2024-09-30 | 107.9 K | Renaissance Technologies Corp | 2024-09-30 | 97 K | Geode Capital Management, Llc | 2024-09-30 | 33.3 K | Two Sigma Investments Llc | 2024-09-30 | 30 K | Hrt Financial Llc | 2024-09-30 | 26.6 K | Fmr Inc | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Stonepine Capital Management Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Vivo Capital, Llc | 2024-09-30 | 6.2 M | Samsara Biocapital, Llc | 2024-09-30 | 3.6 M |
As returns on the market increase, IO Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding IO Biotech is expected to be smaller as well.
IOBT Fundamentals
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.51 | ||||
| Current Valuation | (19.53 M) | ||||
| Shares Outstanding | 65.88 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 76.79 % | ||||
| Number Of Shares Shorted | 85.15 K | ||||
| Price To Book | 0.81 X | ||||
| EBITDA | (91.44 M) | ||||
| Net Income | (86.08 M) | ||||
| Cash And Equivalents | 170.12 M | ||||
| Cash Per Share | 5.90 X | ||||
| Total Debt | 2.49 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 20.94 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (71.74 M) | ||||
| Short Ratio | 1.89 X | ||||
| Earnings Per Share | (1.29) X | ||||
| Target Price | 9.0 | ||||
| Number Of Employees | 74 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 58.63 M | ||||
| Total Asset | 150.72 M | ||||
| Retained Earnings | (263.82 M) | ||||
| Working Capital | 131.54 M | ||||
| Net Asset | 150.72 M |
About IO Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IO Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IO Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IO Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.